Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (320)	2/25/2004 3:07:16 AM
From: Mike Learner	Respond to of 590

5:00PM Abgenix Earnings Correction (ABGX) 14.60 -0.23: -- Update -- Reuters Research is telling us that ABGX reported a net loss of $0.41 per share, excluding charges totalling $17.2 mln pre-tax ($9.3 mln in costs related to starting up co's antibody production facilities and net loss of $7.9 mln associated with investments made in connection with collaborations), $0.05 better than the Reuters Research consensus of ($0.46); revenues rose 102.3% year/year to $6.4 mln vs the $2.9 mln consensus.